- Home
- FKWL vs MREO Comparison
FKWL vs MREO Comparison
Compare FKWL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FKWL | MREO |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7M | 52.5M |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FKWL | MREO |
|---|---|---|
| Price | $3.48 | $0.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $6.00 | $1.50 |
| AVG Volume (30 Days) | 7.9K | ★ 1.6M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 16.67 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $46,086,901.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $7.14 | $55.51 |
| P/E Ratio | $34.80 | ★ N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $3.41 | $0.20 |
| 52 Week High | $5.48 | $2.94 |
Technical Indicators
Market Signals| Indicator | FKWL | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 30.38 |
| Support Level | N/A | $0.20 |
| Resistance Level | $4.47 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 5.26 | 20.33 |
Price Performance
Historical ComparisonAbout FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).